Obagi Medical Partners with VIO Med Spa for Real-World Evidence Study on saypha® MagIQ™
Event summary
- Obagi Medical, part of Waldencast plc (NASDAQ: WALD), has partnered with VIO Med Spa for the ALOHA Program to evaluate Obagi® saypha® MagIQ™ in real-world settings.
- VIO Med Spa was chosen for its rapid growth and expertise in advanced aesthetic treatments across its national network of locations.
- The program will collect standardized data on clinical performance and patient experience across VIO Med Spa’s practices.
- Obagi® saypha® MagIQ™ uses MACRO Core Technology to deliver natural-looking results with high usable hyaluronic acid content.
The big picture
This collaboration underscores the growing emphasis on real-world evidence in the aesthetic medicine sector, as brands seek to differentiate themselves through performance data. Waldencast’s strategic focus on high-growth, purpose-driven brands aligns with Obagi Medical’s expansion into physician-dispensed skincare and injectable solutions. The partnership also highlights the increasing importance of med spa networks as key partners in clinical evaluations.
What we're watching
- Program Outcomes
- How the real-world evidence from the ALOHA Program will impact Obagi® saypha® MagIQ™’s market positioning and adoption.
- Scalability
- Whether VIO Med Spa’s national network can effectively scale the evaluation to provide robust, actionable insights.
- Competitive Dynamics
- The pace at which competitors may respond with similar real-world evidence initiatives for their products.